Silo pharma announces $2.1 million registered direct offering priced at-the-market under nasdaq rules

Sarasota, fl, july 19, 2024 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into definitive agreements for the purchase and sale of 763,638 shares of common stock at a purchase price of $2.75 per share in a registered direct offering priced at-the-market under nasdaq rules. in a concurrent private placement, the company will issue unregistered warrants to purchase up to 763,638 shares of common stock at an exercise price of $2.75 per share that will be immediately exercisable upon issuance and will expire five years following the date of issuance. the closing of the offering is expected to occur on or about july 22, 2024, subject to the satisfaction of customary closing conditions.
SILO Ratings Summary
SILO Quant Ranking